Cambridge Investment Research Advisors, Inc. Ligand Pharmaceuticals Inc Transaction History

Cambridge Investment Research Advisors, Inc.

$29.6 Billion
Q1 2025

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$113.03 - $155.64 $187,403 - $258,051	-1,658 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$99.52 - $215.83 $165,004 - $357,846	1,658 New	1,658 $252,000
Q4 2020 Feb 04, 2021	SELL	$80.55 - $106.05 $217,082 - $285,804	-2,695 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$89.56 - $126.72 $241,364 - $341,510	2,695 New	2,695 $256,000
Q2 2019 Aug 15, 2019	SELL	$107.38 - $129.34 $181,686 - $218,843	-1,692 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$105.93 - $142.47 $17,266 - $23,222	163 Added 10.66%	1,692 $0
Q4 2018 Feb 05, 2019	SELL	$128.36 - $272.13 $13,349 - $28,301	-104 Reduced 6.37%	1,529 $207,000
Q3 2018 Nov 02, 2018	BUY	$211.18 - $274.49 $21,962 - $28,546	104 Added 6.8%	1,633 $0
Q2 2018 Aug 10, 2018	SELL	$150.77 - $207.98 $7,538 - $10,399	-50 Reduced 3.17%	1,529 $0
Q1 2018 May 09, 2018	BUY	$138.63 - $182.62 $218,896 - $288,356	1,579 New	1,579 $0

Others Institutions Holding LGND

# of Institutions

278

Shares Held

18.5M

Call Options Held

30.8K

Put Options Held

5.2K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.85B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account